Brazil’s Natura is extending its innovation agenda into biotechnology through a new investment in Antarka, a Uruguayan startup developing skin longevity solutions based on microorganisms from Antarctica. Antarka has raised a $3.5 million seed round co-led by Natura Ventures and biotech-focused Latin American fund Zentynel, although the amount committed by each investor has not been disclosed publicly. The deal brings together a corporate beauty investor, specialist venture capital, and international backers in a move that reflects growing interest in science-driven skincare innovation.
Strategic Backing
The financing round also included participation from U.S.-based deep tech investor SOSV and South Korean firms GS Futures and CTK, giving Antarka both additional capital and a broader international network. Beyond the financial contribution, Natura said the partnership is designed to support product development and accelerate Antarka’s path to market through access to laboratories, research capabilities, and operational know-how. Under the agreement, Natura has also secured exclusivity for the first development cycle over the next 24 months, a provision that could help it translate Antarka’s research into early commercial applications.
Scientific Foundation
Antarka’s technology stems from research linked to Uruguay’s University of the Republic and focuses on Antarctic photolyases, enzymes that can help repair DNA damage caused by ultraviolet radiation. These enzymes are derived from extremophile microorganisms adapted to survive in some of the harshest environmental conditions on Earth, giving the company a distinctive scientific platform for cosmetic and skin health applications. Rather than emphasizing only the slowing of visible aging, the company’s proposition centers on cellular repair and regeneration, which executives involved in the project describe as a more advanced approach to long-term skin health.
Commercial Expansion
The new capital is expected to be used to expand Antarka’s scientific and commercial teams, increase production capacity, and advance further research as the company prepares for broader commercialization. Antarka is already producing its active ingredient at a pre-industrial scale and is positioning itself to meet regional demand before expanding into larger international markets. Asia and the United States are viewed as priority targets, and the presence of South Korean and U.S. investors could help the startup open doors in highly competitive cosmetics ecosystems.
Strategic Fit for Natura
For Natura, the investment fits within a wider strategy of strengthening its innovation pipeline in Latin America while responding to rising demand for products aimed at healthy aging and the so-called silver generation. Company executives have indicated that Antarka’s platform could reduce development timelines for new skin health products from more than six years to roughly three, allowing the group to test new concepts faster and integrate them into established lines such as Chronos. The transaction is also notable because it marks the fourth investment made by Natura Ventures and its first in biotechnology since the fund was launched in 2024.
The Antarka round highlights how beauty companies are increasingly looking beyond traditional formulation methods and toward frontier science to differentiate future products. By combining Antarctic-derived biotechnology with Natura’s scale, infrastructure, and consumer reach, the partnership creates a test case for whether advanced cellular repair can become commercially viable in mainstream skincare. As Antarka moves from research to industrial and market execution, the company’s progress will be closely watched by investors and cosmetics groups looking for the next wave of high-performance skin health innovation.